A型血友病因子VIII替代治疗药效学监测:凝血酶与纤溶酶生成联合检测
该研究纳入25例A型血友病患者,在单剂25-50 IU/kg标准半衰期FVIII浓缩物药代动力学研究中,用Nijmegen止血试验同步检测凝血酶生成与纤溶酶生成。结果显示FVIII活性与凝血酶生成参数变化不同步,24小时凝血酶生成仍较高,严重患者纤溶酶生成亢进经FVIII补充后正常化。
要点
- FVIII活性15分钟升至71 IU/dL,24小时降至15 IU/dL,凝血酶生成24小时仍较高。
- 基线FVIII活性相近的患者凝血酶与纤溶酶生成存在明显差异。
- 严重A型血友病患者纤溶酶生成亢进,补充FVIII后恢复正常。
核心结论
- A型血友病患者基线凝血酶生成与纤溶酶生成存在明显差异,尽管FVIII活性水平相当。
- FVIII活性水平与凝血酶生成之间存在不一致,后者可能是监测个体化治疗更好的参数。
研究设计与样本
- 纳入25例A型血友病患者(基线FVIII < 1-9 IU/dL),进行单剂25-50 IU/kg标准半衰期FVIII浓缩物的药代动力学研究。
- 在基线和给药后,用Nijmegen止血试验(NHA)检测凝血酶生成(TG)与纤溶酶生成(PG)参数。
主要发现
- FVIII活性从基线中位数1.0 IU/dL(四分位距<1.0-6.0)升至给药后15分钟71 IU/dL(62-82),24小时降至15 IU/dL(10-26)。
- 凝血酶峰值从22nM(15-35)升至222nM(159-255),凝血酶潜力从404nM/min(不可测-876)升至1834nM/min(1546-2353)。
- 给药后24小时凝血酶生成参数仍较高:凝血酶峰值73nM(58.5-126.3),凝血酶潜力1394nM/min(1066-1677)。
- 与轻型患者和对照相比,重型A型血友病患者纤溶酶生成亢进,补充FVIII后恢复正常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical severity of hemophilia A (HA) varies, possibly due to interplay of many factors in the hemostatic pathway. Pharmacokinetic monitoring of factor VIII (FVIII) replacement therapy in HA patients consists of measuring FVIII activity levels and subsequent dose adjustment. The Nijmegen Hemostasis Assay (NHA) measures thrombin generation (TG) and plasmin generation (PG). OBJECTIVE: To determine differences in TG and PG between HA patients before and during a pharmacokinetic study and identify best parameters to develop a pharmacodynamic model. METHODS: Twenty-five HA patients (baseline FVIII < 1-9 IU/dL) underwent a pharmacokinetic study with a single dose of 25-50 IU/kg standard half-life FVIII concentrate. At baseline and after administration of FVIII TG and PG parameters were measured with the NHA. RESULTS: FVIII activity level increased from median 1.0 IU/dL (interquartile range < 1.0-6.0) to 71 IU/dL (62-82) 15 minutes after administration and decreased to 15 IU/dL (10-26) at 24 hours. TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15-35) to 222nM (159-255), and thrombin potential (TP) from 404nM/min (undetectable-876) to 1834nM/min (1546-2353). Twenty-four hours after infusion, TG parameters remained high (TPH 73nM [58.5-126.3]; TP 1394nM/min [1066-1677]) compared to FVIII activity level. PG showed hyperfibrinolysis in severe HA patients compared to mild patients and controls, which normalized after FVIII supplementation. CONCLUSION: HA patients showed clear differences in baseline TG and PG despite having comparable FVIII activity levels. These results reveal a discrepancy between FVIII activity level and TG, in which the latter may be a better parameter to monitor individualized treatment in HA patients.
引用
- Valke LLFG, Bukkems LH, Barteling W, et al. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. J Thromb Haemost. 2020. PMID: 32979031. doi:10.1111/jth.15106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。